SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kyverna Therapeutics announces completion of bla submission for Miv-cel in Stiff Person Syndrome and reports third quarter 2026 financial re

Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first ap

KYTX

Related stories